2011 - 2015年南通市开发区居民恶性肿瘤死亡情况分析

目的 分析2011 - 2015年南通市开发区居民恶性肿瘤的死亡流行特征，为恶性肿瘤防治工作提供科学依据。方法 应用死亡率、标化死亡率、潜在减寿年数(PYLL)、潜在减寿率 (PYLLR)和平均减寿年数(AYLL)计算恶性肿瘤的各种死亡指标。结果 2011 - 2015年南通市开发区居民因恶性肿瘤死亡占总死亡人数的37.74%。恶性肿瘤死亡率和标化死亡率分别为200.62/10万和98.00/10万。2011 - 2015年恶性肿瘤粗死亡率呈上升趋势(t = 4.36，P＜0.05)。男性恶性肿瘤死亡率是女性的1.82倍。肺癌死亡率为52.39/10万，居恶性肿瘤死亡率首位。PYLLR排序前3位依次为肝癌(3.12‰)、肺癌(2.43‰)和胃癌(1.14‰)。居AYLL前3位的恶性肿瘤依次为白血病(18.00人年)、乳腺癌(17.25人年)和肝癌(14.41人年)。结论 南通市开发区居民恶性肿瘤防治的重点为死亡率和潜在减寿率较高的肺癌、肝癌、胃癌以及平均减寿年数较高的白血病、女性的乳腺癌，应针对重点癌种和人群，开展综合防治措施。

Analysis on death of malignant cancer for the residents of Nantong development between 2011 and 2015

Objective To analyze the epidemiological features of malignant cancer in Nantong development area residents between 2011 and 2015, so as to provide a scientific basis for preventing and controlling of malignant cancer. Methods The mortality and loss of life were determined by analyzing mortality, standardized mortality, potential years of life lost (PYLL), potential years of life lost rate (PYLLR) and average years of life lost (AYLL). Results A total of 1 482 death cases were died from cancer, which accounting for 37.74% of the total deaths. The crude mortality and age-standardized mortality were 200.62/100 000 and 98.00/100 000, respectively. The death rate of cancer increased significantly(t=4.36, P<0.05) from 2011 to 2015. The mortality of malignant cancer was significantly higher in males than in females, it was 1.82 times as women. The mortality of lung cancer was 52.39/100 000. According to the PYLL rate, the top 3 of cancers were liver cancer (3.12‰), lung cancer (2.43‰) and stomach cancer (1.14‰), respectively. The top 3 cancers of AYLL were leukemia (18.00 person years), breast cancer(17.25 person years) and liver cancer(14.41 person years), respectively. Conclusion The focus of malignant cancer prevention was death and early death in whole population were lung cancer, liver cancer, stomach cancer and leukemia, as well as and breast cancer in the female. Comprehensive control measures should be carried out for these cancers with greater burden.